Definium Therapeutics, Inc.(DFTX)Fundamental Analysis & FinancialsNASDAQ
Valuation, growth, margins and balance sheet
Valuation Snapshot
What the multiples imply about expectations
Market value is $4.47B, which makes it a mid-cap company (market value of $2B to $10B). Price-to-book is 4.87, at or below 5.
Valuation Metrics
Ratios and multiples
Financial Health
Liquidity and leverage
The company's financial health appears moderate. Moderate ROE and moderate ROA reflect reasonably efficient capital use. Debt is manageable within acceptable ranges.
Valuation Multiples
Current valuation metrics
Quarterly Earnings History
Recent quarterly financial performance and trends
| Quarter | Revenue | Net Income | Gross Profit | EPS (Basic) | EPS (Diluted) | Gross Margin | Net Margin |
|---|---|---|---|---|---|---|---|
| Jun 2026(Latest) | $0.00 | -$158.99M | N/A | -$1.44 | -$1.44 | N/A | N/A |
| Mar 2026 | $0.00 | -$77.10M | N/A | -$0.71 | -$0.71 | N/A | N/A |
| Dec 2025 | $0.00 | -$50.44M | N/A | N/A | N/A | N/A | N/A |
| Sep 2025 | $0.00 | -$67.27M | N/A | -$0.78 | -$0.78 | N/A | N/A |
| Jun 2025 | $0.00 | -$42.74M | N/A | -$0.50 | -$0.50 | N/A | N/A |
Key Insights:
- EPS declined by 102.8% quarter-over-quarter
Financial Efficiency
Utilization and collections performance
ROIC -94.9% highlights weak capital returns.
Efficiency Metrics
Profitability & Growth
Margins and earnings power
Efficiency Performance Matrix
4-quadrant analysis of operational efficiency vs profitability
Efficiency vs Profitability Quadrants
High Margin
Low Margin
High Margin
Low Margin
Efficiency Analysis
Asset Turnover
Receivables Turnover
Working Capital
Overall Efficiency Score
Insufficient data for operational analysis
⚠️ Thresholds are benchmark-based heuristics derived from long-term industry averages, not strict valuation rules.
• Bubble size represents ROIC magnitude
• Green (Optimal): Excellent efficiency-profitability balance
• Blue (Efficiency-Driven): High turnover, room to improve margins
• Yellow (Margin-Driven): Strong margins, opportunity to improve efficiency
• Red (Weak Operations): Areas needing improvement on both dimensions
Market Data & Share Structure
Comprehensive valuation metrics and ownership breakdown
Market Data & Capitalization
Share Statistics & Ownership
Profitability Margin Pyramid
Hierarchical view of margin compression from revenue to net income
Margin Hierarchy by Profitability Level
Margin Analysis
Total Revenue
Gross Profit
EBITDA
Net Income
• Larger circles represent higher dollar amounts
• Margin percentages show profitability at each level
• Blue: Revenue base
• Green: Gross profitability
• Yellow: Operating performance
• Red: Net profitability
Operating Cash & Liquidity
Core cash generation and short-term solvency
Cash Flow Analysis
Operating Cash Flow (TTM)
-$167.95M
Cash from core operations
Free Cash Flow (TTM)
-$167.95M
Available after capex
Financial Position & Liquidity
Current Ratio
6.95
Healthy
Quick Ratio
6.90
Strong
Net Cash
$1.05B
Net creditor
Total Cash
$1.08B
Balance sheet cash
Total Debt
$36.47M
Outstanding borrowings
Ownership & Shareholder Sentiment
Insider, institutional, and short interest positions
Insider Ownership
2.57%
Moderate stake
Institutional Ownership
96.39%
Majority backing
Short % of Float
7.52%
Notable short
Short Ratio (Days)
4.3d
days to cover
Ownership structure shows limited insider stake and institutional majority backing.
Dividends & Shareholder Returns
Policy stance and implications
The company does not currently pay a regular dividend.
Explore More Analysis for DFTX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Latest TickZen Insights
AbbVie (ABBV) Q3 2026 Earnings Preview: Will Skyrizi and Rinvoq be able to justify the 20x?By Vishal Jadaun · 
Alphabet (GOOG) Q3 2026 Earnings Preview: Will Cloud Overtake Capex?By Vishal Jadaun · 
HSBC Q3 2026 Earnings Preview: Is the $46bn NII Guide Too Low?By Vishal Jadaun ·